Tumor-infiltrating FoxP3+ tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients

Digestion

Volumn 86, Issue 4, 2013, Pages 329-337

  Huang, Yong ^a,b   Wang, Feng Mei ^a,b   Wang, Tao ^b   Wang, Yi Jun ^b   Zhu, Zheng Yan ^c   Gao, Ying Tang ^c   Du, Zhi ^b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Department of Gastroenterology and Hepatology ^*  (China)

^c THIRD CENTRAL HOSPITAL OF TIANJIN   (China)

Author keywords

Angiogenesis; Carcinoma; CD8; FoxP3; Hepatocellular; Prognosis

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CELL DENSITY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

ADULT; ANTIGENS, CD34; ANTIGENS, CD4; ANTIGENS, CD8; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICROVESSELS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84870299577     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000342801     Document Type: Article

References (47)

1. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
2. Hao XS, Wang PP, Chen KX, et al: Twentyyear trends of primary liver cancer incidence rates in an urban Chinese population. Eur J Cancer Prev 2003; 12: 273-279.
3. Korangy F, Ormandy LA, Bleck JS, et al: Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 4332-4341.
4. Kuang DM, Peng C, Zhao Q, et al: Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T-helper 17 cells. Hepatology 2010; 51: 154-164.
5. Budhu A, Forgues M, Ye QH, et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111.
6. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
7. Hiraoka N: Tumor-infiltrating lymphocytes and hepatocellular carcinoma: Molecular biology. Int J Clin Oncol 2010; 15: 544-551.
8. Gajewski TF: The expanding universe of regulatory T-cell subsets in cancer. Immunity 2007; 27: 185-187.
9. Wang HY, Wang RF: Regulatory T cells and cancer. Curr Opin Immunol 2007; 19: 217-223.
10. Bettelli E, Carrier Y, Gao W, et al: Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441: 235-238.
11. Longhi MS, Hussain MJ, Mitry RR, et al: Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006; 176: 4484-4491.
12. Yoshizawa K, Abe H, Kubo Y, et al: Expansion of CD4+CD25+FoxP3+ regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma. Hepatol Res 2010; 40: 179-187.
13. Sakaki M, Hiroishi K, Baba T, et al: Intrahepatic status of regulatory T cells in autoimmune liver diseases and chronic viral hepatitis. Hepatol Res 2008; 38: 354-361.
14. Liyanage UK, Moore TT, Joo HG, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756-2761.
15. Ichihara F, Kono K, Takahashi A, et al: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9: 4404-4408.
16. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
17. Loddenkemper C, Hoffmann C, Stanke J, et al: Regulatory (FoxP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer. Cancer Sci 2009; 100: 1112-1117.
18. Chen YL, Fang JH, Lai MD, et al: Depletion of CD4+CD25+ regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma. World J Gastroenterol 2008; 14: 5797-5809.
19. Nagayama Y, Hase W, Motoyoshi Y, et al: Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells. Oncol Rep 2007; 17: 1269-1273.
20. Kobayashi N, Hiraoka N, Yamagami W, et al: FoxP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 902-911.
21. Antony PA, Piccirillo CA, Akpinarli A, et al: CD8+ T-cell immunity against a tumor/selfantigen is augmented by CD4+ T-helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174: 2591-2601.
22. Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-2593.
23. Llovet JM, Fuster J, Bruix J; Barcelona Clinic Liver Cancer Group: The Barcelona Approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant 2004; 10: 115-120.
24. Hirohashi S, Ishak KG, Kojiro M, et al: Hepatocellular carcinoma; in Hamilton SR, Aaltonen LA (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon, IARC Press, 2000, pp 159-172.
25. Saad RS, Luckasevic TM, Noga CM, et al: Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology. Diagn Cytopathol 2004; 30: 1-6.
26. Fu J, Xu D, Liu Z, et al: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339.
27. Sakaguchi S, Sakaguchi N, Asano M, et al: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor -chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
28. Mills KH: Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4: 841-855.
29. Chang KM: Regulatory T cells and the liver: A new piece of the puzzle. Hepatology 2005; 41: 700-702.
30. Ormandy LA, Hillemann T, Wedemeyer H, et al: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 2457-2464.
31. Kosmaczewska A, Ciszak L, Potoczek S, et al: The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp 2008; 56: 181-191.
32. Roncador G, Brown PJ, Maestre L, et al: Analysis of FoxP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2006; 36: 1681-1691.
33. Crispe IN: The liver as a lymphoid organ. Annu Rev Immunol 2009; 27: 147-163.
34. Toh H, Phoon YP, Quek R, et al: Increased FoxP3+ regulatory T cells predicts for superior relapse-free and overall survival in early stage hepatocelullar carcinoma. J Clin Oncol 2007; 25: 4642.
35. Gao YW, Chen YX, Wang ZM, et al: Increased expression of cyclooxygenase-2 and increased infiltration of regulatory T cells in tumors of patients with hepatocellular carcinoma. Digestion 2009; 79: 169-176.
36. Zhang JY, Song CH, Shi F, et al: Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS ONE 2010; 5:e13869.
37. Yang XH, Yamagiwa S, Ichida T, et al: Increase of CD4+CD25+ regulatory T cells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006; 45: 254-262.
38. Unitt E, Rushbrook SM, Marshall A, et al: Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 2005; 41: 722-730.
39. Thornton AM, Shevach EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T-cell activation in vitro by inhibiting interleukin-2 production. J Exp Med 1998; 188: 287-296.
40. Biswas SK, Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-896.
41. Wada J, Suzuki H, Fuchino R, et al: The contribution of vascular endothelial growth factor to the induction of regulatory T cells in malignant effusions. Anticancer Res 2009; 29: 881-888.
42. Gupta S, Joshi K, Wig JD, et al: Intratumoral FoxP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol 2007; 46: 792-797.
43. Facciabene A, Peng X, Hagemann IS, et al: Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 2011; 475: 226-230.
44. Stoop JN, van der Molen RG, Kuipers EJ, et al: Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007; 361: 141-148.
45. Wang F, Jing X, Li G, et al: FoxP3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma. Liver Int 2012; 32: 644-655.
46. Zhou L, Fu JL, Lu YY, et al: Regulatory T cells are associated with postcryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol 2010; 45: 968-978.
47. De Rezende LC, Silva IV, Rangel LB, et al: Regulatory T cell as a target for cancer therapy. Arch Immunol Ther Exp 2010; 58: 179-190.